Prognostic factors of advanced stage non-small-cell lung cancer
Keywords:
non-small-cell lung cancer, prognosis, survivalAbstract
Abstract:
Background: Lung cancer is the main cause of death from cancer in the world. The 5-year survival is about 15%. Despite the progress of medicine the mortality rate decreased only marginally. This poor prognosis is due to late diagnosis.
Aim: To evaluate overall survival and prognostic factors in patients locally advanced or metastatic non small cell lung cancer (NSCLC).
Methods: Retrospective study including 180 patients with non-small cell lung cancer hospitalized in the department of Charles Nicolle Hospital of Tunis between January 2007 and December 2014.
Results: The mean age was 61.5 years with a male predominance (93.3%). The median overall survival was 6 months. The poor prognostic factors were the performans status (PS) and early delays of management (<30 days). The factors that improve survival were surgical treatment and delays of management more than 45 days.
Conclusion: The prognostic factors in locally advanced and metastatic NSLC in our patient were: PS, management delay and treatment. These factors should be considered in management of patient with advanced stage NSCLC.
Downloads
References
Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104:569-77.
Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier A. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 2008;44:115-22.
Statistiques sanitaires mondiales 2012. Bibliothèque OMS 2012.
Ben Abdallah, M., Zehani, S., & Hizem Ben Ayoub, W. (2009). Registre des Cancers Nord-Tunisie. Ministre de la Sante Publique Institut Salah Azaiez Institut National de la Sante Publique, Tunis, Tunisia.
Dautzenberg B, Choukroun G. Cancers bronchopulmonaires primitifs non à petites cellules et tumeurs à malignité réduite. Encycl Méd Chir ( Elsevier Masson, Paris), Pneumologie 1998 :1-16.
Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier A et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007;43:149-60.
De Carol P, Benfield J. Lung cancer in young persons. J Thorac Cardiovasc Surg 1982;83:372—6.
Sugio K, Ishida T, Kaneko S, et al. Surgically resected lung cancer in young adults. Ann Thorac Surg 1992;53:127-31.
Dujon C, Azarian R, Petitpretz P. Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d'une série rétrospective. Rev Mal Respir 2009;26:952-60.
Chermiti Ben Abdallah F, Ben Ali G, Sadok Boudaya M, Milka M, Chtourou A, Taktak S et al. Traitement et pronostic du cancer bronchique non à petites cellules au stade avancé. Rev Mal Respir 2014;31:214-20.
Moro D, Nagy-Mignotte H, Bolla M, Colonna M, Brichon PY, Brambilla C, Schaerer R, Vrousos C : Evaluation de la survie et des facteurs pronostiques de 2000 cancers broncho-pulmonaires enregistrés en 10 ans dans une unité multidisciplinaire de cancérologie. Bull Cancer 1997;84:155-61.
Paesmans M : Les facteurs pronostiques. Rev Mal Respir 2008;25:3S99-106.
Finkelstein DM, Ettinger DS, Ruckdeschel JC : Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-9.
Wataya H, Okamoto T, Maruyama R, et al. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer 2009;64:341-5.
Grivaux M, Zureik M, Marsal L, et al. Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2009;26:37-44.
D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:116-9.
Widikker G, Rochat T, Simonet M. Non small cell lung cancer and thoracic surgery: the role of the primary care physician. Rev Médicale Suisse 2008;4:2208-11. 18. Moro-Sibilot D, Pluquet E, Zalcman G, et al. Quel traitement pour un patient de PS 2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ? Rev Mal Respir 2007;24:120-4.
Mornex F, Martin E, Belliére A, Milleron B, Van Houtte P, Chapet O. Cancer bronchique non à petites cellules localement évolué: place de la chimiothérapie exclusive. Cancer Radiother. 2002;6:117-24.
Patel S, Sanborn R, Thomas CJ. Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease. Thorac Surg Clin 2008;18:393-401.
Furuse K, Fukuoka M, Kawahara M. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
Chargari C, Deutsch E, Le Péchoux C. États des lieux desassociations chimioradiothérapeutiques et place potentielledes thérapies ciblées dans les cancers non à petites cellules 2009;13:114-22.
Christensen E, Harvald T, Jendresen M. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997;12:880-4.
Kashiwabara K, Koshi S, Itonaga K. Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. Lung Cancer 2002;35:237-41.
Yorio J, Xie Y, Yan J, Gerber D. Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 2009;4:1322-30.
Quarterman R, McMillan A, Ratcliffe M. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;125:108-13.
Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 2001;34:243-52.
Aragoneses F, Moreno N, Leon P. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002;36:59-63.
Salomaa E, Sällinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-8.
Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M : 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;8: 1-8.
